HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome.

Abstract
Autosomal dominant hyper-IgE syndrome (AD-HIES) is caused by dominant-negative mutations in STAT3; however, the molecular basis for mutant STAT3 allele dysfunction is unclear and treatment remains supportive. We hypothesized that AD-HIES mutations decrease STAT3 protein stability and that mutant STAT3 activity can be improved by agents that increase chaperone protein activity. We used computer modeling to characterize the effect of STAT3 mutations on protein stability. We measured STAT3 protein half-life (t1/2) and determined levels of STAT3 phosphorylated on tyrosine (Y) 705 (pY-STAT3) and mRNA levels of STAT3 gene targets in Epstein-Barr virus-transformed B (EBV) cells, human peripheral blood mononuclear cells (PBMCs), and mouse splenocytes incubated without or with chaperone protein modulators-HSF1A, a small-molecule TRiC modulator, or geranylgeranylacetone (GGA), a drug that upregulates heat shock protein (HSP) 70 and HSP90. Computer modeling predicted that 81% of AD-HIES mutations are destabilizing. STAT3 protein t1/2 in EBV cells from AD-HIES patients with destabilizing STAT3 mutations was markedly reduced. Treatment of EBV cells containing destabilizing STAT3 mutations with either HSF1A or GGA normalized STAT3 t1/2, increased pY-STAT3 levels, and increased mRNA levels of STAT3 target genes up to 79% of control. In addition, treatment of human PBMCs or mouse splenocytes containing destabilizing STAT3 mutations with either HSF1A or GGA increased levels of cytokine-activated pY-STAT3 within human CD4+ and CD8+ T cells and numbers of IL-17-producing CD4+ mouse splenocytes, respectively. Thus, most AD-HIES STAT3 mutations are destabilizing; agents that modulate chaperone protein function improve STAT3 stability and activity in T cells and may provide a specific treatment.
AuthorsClaire E Bocchini, Karen Nahmod, Panagiotis Katsonis, Sang Kim, Moses M Kasembeli, Alexandra Freeman, Olivier Lichtarge, George Makedonas, David J Tweardy
JournalBlood (Blood) Vol. 128 Issue 26 Pg. 3061-3072 (12 29 2016) ISSN: 1528-0020 [Electronic] United States
PMID27799162 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • DNA-Binding Proteins
  • Diterpenes
  • Heat Shock Transcription Factors
  • Interleukin-17
  • Mutant Proteins
  • STAT3 Transcription Factor
  • Transcription Factors
  • Phosphotyrosine
  • geranylgeranylacetone
Topics
  • Animals
  • CD4-Positive T-Lymphocytes (drug effects, immunology)
  • CD8-Positive T-Lymphocytes (drug effects, immunology)
  • Cytokines (pharmacology)
  • DNA-Binding Proteins (metabolism)
  • Diterpenes (pharmacology)
  • Half-Life
  • Heat Shock Transcription Factors
  • Herpesvirus 4, Human (physiology)
  • Humans
  • Interleukin-17 (metabolism)
  • Job Syndrome (metabolism, pathology)
  • Mice
  • Models, Molecular
  • Mutant Proteins (metabolism)
  • Mutation (genetics)
  • Phosphotyrosine (metabolism)
  • Protein Binding (drug effects)
  • Protein Stability (drug effects)
  • STAT3 Transcription Factor (chemistry, genetics, metabolism)
  • Spleen (pathology)
  • Transcription Factors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: